XERS - Xeris Pharmaceuticals GAAP EPS of -$0.10 in-line revenue of $44.39M beats by $0.84M
2024-03-06 07:03:17 ET
More on Xeris Pharmaceuticals
- Xeris Biopharma: Speculative Buy, Size Your Position Accordingly
- Xeris Biopharma Holdings Stock Is A Hold With Robust Performance Into 2024
- Xeris Pharmaceuticals Q4 2023 Earnings Preview
- Amgen in pact with Xeris Biopharma for Tepezza injectable
- Seeking Alpha’s Quant Rating on Xeris Pharmaceuticals